The expression of resistance-related genes in ovarian cancer paclitaxel-resistancer cell after paclitaxel chemotherapy in vitro
- Author:
- No author available
- Journal Title:
- CHINA CLINICAL PRACTICAL MEDICINE
- Issue:
- 11
- DOI:
- No doi available
- Key Word:
- 卵巢癌;培养的肿瘤细胞;耐药性;基因表达;Ovarian caner;Cultured tumor cell;Drug resistance;Gene expression
Abstract： Objective To investigate expression of several drug resistance related genes between sensitive and resistant ovarian cancer cell lines after paditaxel chemotherapy in vitro.Methods RT-PCR method was used to detect the expressions of several drug resistance related genes between ovarian cancer cell A2780 and paelitaxel-resistant A2780/TS.Results In paclitaxel-resistant cell line A2780/TS,the inhibit rate was much lower than that in sensitive cell line A2780(P＜0.01).The resistance index(RI)of A2780/TS cell was 3.650.There was no significant differencesinG1、G2、and S ratio between the A2780 and A2780/TS cells(P＞0.05).Among those resistance related genes,multiple drug resistance(MDR-1)gene,P53 were expressed at lower leveh in resistant A2780/TS cells than in sensitive A2780 cells;while cytochrome P450 1B1(CYP1B1)and apoptotic inhibit protein survivin were expressed higher,and no obvious alterations were found concerning glutathione S transforase-pi(GST-Pi)and multiple drug resistance related protein-1(MRP-1).Conclusion The expression of known drng resistance related genes were distantly different in paclitaxel resistant and sensitive cell lines,suggesting more than one pathway leading to resistance transformation.It is necessary to study and validate widely,deeply and completely for setting down clinical chemotherapy method and reversing arug resistance.
- [1]Xue-Dong, Yan,Min, Li,Ye, Yuan,etc.Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.[J].2007,17(5).
- [2]C E, Grant,G, Valdimarsson,D R, Hipfner,etc.Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs.[J].1994,54(2).
- [3]Wang K,Shu Y,Lu D,etc.Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.[J].2008,26(4).
- [4]Rochat B.Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.[J].2005,44(4).
- [5]Perez Tomas R.Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.[J].2006,13(16).
- [6]Scripture CD,Sparreboom A,Figg WD.Modulation of cytochrome P450 activity: implications for cancer therapy.[J].2005,6(10).
- [7]Nakajima M,Yokoi T.Cancer pharmacogenomics: achievements in basic research.[J].2005,10(1).
- [8]McGrogan BT,McCann A,Gilmartin B,etc.Taxanes, microtubules and chemoresistant breast cancer.[J].2008,1785(2).
- [9]Fujita K.Cytochrome P450 and anticancer drugs.[J].2006,7(1).
- [10]N. Zaffaroni,M. Pennati,S. Pilotti,etc.Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer[J].2002,59(8).